Tax withholding sales by AN2 Therapeutics (ANTX) CFO Lucy Day filing

Rhea-AI Filing Summary

AN2 Therapeutics, Inc. Chief Financial Officer Lucy Day reported two sales of company common stock. On January 5, 2026, she sold 3,295 shares at $1.003 per share, and on January 6, 2026, she sold 5,512 shares at $1.012 per share. According to the disclosure, these sales were made under the terms of the equity grant to satisfy tax withholding obligations arising from the vesting of restricted stock units on January 1, 2026.

After these transactions, Day directly holds 75,363 shares of AN2 Therapeutics common stock. Her equity awards also include 27,500 RSUs that vest in four annual installments starting January 1, 2024, and 46,500 RSUs that vest in four annual installments starting January 1, 2025, in each case subject to her continued service. The reported total reflects a prior purchase of 5,000 shares through the company’s employee stock purchase plan on September 30, 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Day Lucy

(Last) (First) (Middle)

C/O AN2 THERAPEUTICS, INC.

1300 EL CAMINO REAL, SUITE 100

(Street)

MENLO PARK CA 94025

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
AN2 Therapeutics, Inc. [ ANTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/05/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/05/2026		S		3,295(1)	D	$1.003	80,875(2)(3)	D
Common Stock	01/06/2026		S		5,512(1)	D	$1.012	75,363(2)(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares sold pursuant to the terms of the grant to satisfy tax withholding obligations arising from the vesting of Restricted Stock Units ("RSUs") on January 1, 2026.

2. Includes (a) 27,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2024 and (b) 46,500 RSUs which vest as follows: 1/4th of the RSUs vest annually over four years from January 1, 2025, in each case subject to the Reporting Person continuing to provide services to the Company as an employee, consultant or director of the Company through each applicable vesting date.

3. Reflects the adjusted total which includes the purchase of 5,000 shares under the Issuer's Employee Stock Purchase Plan on September 30, 2025.

	/s/ Lucy Day	01/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

Who is the insider in ANTX’s latest Form 4 filing?

The insider is Lucy Day, the Chief Financial Officer of AN2 Therapeutics, Inc. (ANTX), who filed as a reporting person for these equity transactions.

How many AN2 Therapeutics (ANTX) shares did the CFO sell and at what prices?

Lucy Day reported selling 3,295 shares of common stock at $1.003 per share on January 5, 2026, and 5,512 shares at $1.012 per share on January 6, 2026.

What was the purpose of the ANTX share sales reported by the CFO?

The filing states the shares were sold to satisfy tax withholding obligations arising from the vesting of restricted stock units (RSUs) on January 1, 2026, in accordance with the terms of the grant.

How many AN2 Therapeutics (ANTX) shares does the CFO hold after these transactions?

Following the reported sales, Lucy Day directly owns 75,363 shares of AN2 Therapeutics common stock.

What RSU awards for ANTX stock are outstanding for the CFO?

The disclosure notes 27,500 RSUs vesting over four years with annual vesting starting January 1, 2024, and 46,500 RSUs vesting over four years with annual vesting starting January 1, 2025, each subject to her continued service.

Does the Form 4 mention any AN2 Therapeutics employee stock purchase activity?

Yes. The reported total holdings include an earlier purchase of 5,000 shares under AN2 Therapeutics’ Employee Stock Purchase Plan on September 30, 2025.